Page last updated: 2024-08-26

bosentan anhydrous and Hepatitis B

bosentan anhydrous has been researched along with Hepatitis B in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fu, L; Gao, F; Huang, S; Zhang, L; Zhao, S; Zhen, Y; Zhou, X1
Descamps, D; Gervais, A; Larrouy, L; Le Beller, C; LĂȘ, MP; Long, K; Mal, H; Papy, E; Peytavin, G1

Other Studies

2 other study(ies) available for bosentan anhydrous and Hepatitis B

ArticleYear
Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.
    Bioorganic & medicinal chemistry letters, 2019, 10-01, Volume: 29, Issue:19

    Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Benzamides; Drug Design; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Humans; Molecular Docking Simulation; Organic Anion Transporters, Sodium-Dependent; Symporters; Virus Internalization

2019
Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:5

    Topics: Antiviral Agents; Bosentan; Drug Interactions; Hepatitis B; Hepatitis C; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Oligopeptides; Sulfonamides

2013